Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Open accessThe DOI matches its Crossref record; 132 of the 133 references it cites were found in a registry or an index; 40 of the 58 sources its claims cite were checked for support.
Abstract
The evolution of drug resistance has a profound impact on human health. Candida glabrata is a leading human fungal pathogen that can rapidly evolve resistance to echinocandins, which target cell wall biosynthesis and are front-line therapeutics for Candida infections. Here, we provide the first global analysis of mutations accompanying the evolution of fungal drug resistance in a human host utilizing a series of C. glabrata isolates that evolved echinocandin resistance in a patient treated with the echinocandin caspofungin for recurring bloodstream candidemia. Whole genome sequencing identified a mutation in the drug target, FKS2, accompanying a major resistance increase, and 8 additional non-synonymous mutations. The FKS2-T1987C mutation was sufficient for echinocandin resistance, and associated with a fitness cost that was mitigated with further evolution, observed in vitro and in a murine model of systemic candidemia. A CDC6-A511G(K171E) mutation acquired before FKS2-T1987C(S663P), conferred a small resistance increase. Elevated dosage of CDC55, which acquired a C463T(P155S) mutation after FKS2-T1987C(S663P), ameliorated fitness. To discover strategies to abrogate echinocandin resistance, we focused on the molecular chaperone Hsp90 and downstream effector calcineurin. Genetic or pharmacological compromise of Hsp90 or calcineurin function reduced basal tolerance and resistance. Hsp90 and calcineurin were required for caspofungin-dependent FKS2 induction, providing a mechanism governing echinocandin resistance. A mitochondrial respiration-defective petite mutant in the series revealed that the petite phenotype does not confer echinocandin resistance, but renders strains refractory to synergy between echinocandins and Hsp90 or calcineurin inhibitors. The kidneys of mice infected with the petite mutant were sterile, while those infected with the HSP90-repressible strain had reduced fungal burden. We provide the first global view of mutations accompanying the evolution of fungal drug resistance in a human host, implicate the premier compensatory mutation mitigating the cost of echinocandin resistance, and suggest a new mechanism of echinocandin resistance with broad therapeutic potential.
Overview
CoChat Summary
## TL;DR
This study tracks echinocandin resistance as it evolved over 10 months in a patient with recurrent *Candida glabrata* candidemia, using whole-genome sequencing plus functional genetics. The main resistance mutation was *FKS2* T1987C (S663P), which was sufficient for resistance but carried a fitness cost that was later mitigated; the paper also shows that Hsp90 and calcineurin are required for resistance and for caspofungin-induced *FKS2* expression.
## Key findings
- Whole-genome sequencing of early isolate A and late isolate G found 26 single-nucleotide variants total, with 17 in open reading frames and 9 non-synonymous mutations; these were mapped across the 7-isolate series.
- The *FKS2* T1987C (S663P) mutation was sufficient to confer echinocandin resistance in a susceptible laboratory strain, but it reduced fitness in RPMI at 37°C; the paper reports this fitness cost was mitigated with further evolution.
- A *CDC6* A511G (K171E) mutation conferred a small increase in echinocandin resistance, and increased dosage of *CDC55* ameliorated the fitness cost associated with the *FKS2* mutation.
- Pharmacological or genetic compromise of Hsp90 or calcineurin reduced basal tolerance/resistance, and caspofungin-induced *FKS2* expression was blocked by deletion of *CNB1* and reduced when *HSP90* was repressed.
- A petite mutant in the series was not intrinsically echinocandin-resistant, but was refractory to the synergy between caspofungin and Hsp90/calcineurin inhibitors; in mice, kidneys infected with the petite mutant were sterile, and reduced *HSP90* lowered kidney fungal burden.
## Methods
- Clinical case series: 7 related *C. glabrata* bloodstream isolates collected over a 10-month period from one patient with recurrent candidemia during caspofungin treatment.
- Genomics and validation: whole-genome sequencing of isolates A and G on Illumina Genome Analyzer II (5.1 and 3.8 million 76-bp reads; 22–30× coverage), alignment to CBS138, variant calling, Sanger validation, and Sanger mapping of candidate mutations across isolates B–F.
- Functional assays: broth microdilution MIC testing, qRT-PCR for *FKS2*, *CNB1*, and *HSP90* expression, growth-curve analysis, engineered mutant/complement strains, and a murine disseminated infection model in CD1 mice (n = 10 per group).
## Limitations
- The paper states that whether the original petite mutant arose in the human host or during sampling “remains unknown.”
- The authors note that methionine levels in mice may not have been sufficient to fully repress the MET3 promoter, which may explain why *HSP90* depletion caused only a modest reduction in fungal burden in vivo.
- Evident from the text: the study centers on a single patient case series, so the clinical evolutionary trajectory is detailed but not shown to be broadly representative.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
26 Valid · 2 Not valid · 8 Not checked · 151 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Thus far, the only echinocandin resistance mechanism described is mutation in the drug target, Fks, particularly in highly conserved hot spots regions [33], [36]–[39].”
§ Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata > Introduction The emergence of drug resistance is an evolutionary process with a profound impact on human health. The widespread deployment of antimicrobial agents in medicine and agriculture exerts strong selection for organisms with enhanced capacity to survive and reproduce in the presence of drug, which has led to the rapid emergence of drug resistance in diverse pathogen populations [1]–[4]. The evolution of drug resistance compromises the efficacy of drugs that we depend on critically for a myriad of therapeutic interventions, and has striking economic consequences. The annual cost attributable to the evolution of drug resistance in the United States alone exceeds $33 billion to cover treatment of patients with drug-resistant infections, additional pesticides required to manage resistant pests, and loss of crops to resistant pests [5]. The emergence of drug resistance in fungal pathogens is of particular concern given the increasing incidence of invasive fungal infections, and the limited number of antifungal drugs. Fungi can cause life-threatening infectious disease in immunocompromised hosts, as well as in healthy humans, and the incidence of fungal bloodstream infections has increased by 207% in recent decades [6]–[8]. Fungi are eukaryotes and share close evolutionary relationships with their human hosts, which limits the number of drug targets that can be exploited to selectively kill fungal pathogens yet minimize host toxicity [1], [3]. Even with current treatment options, mortality rates due to invasive fungal infections can reach 50–90% depending on the pathogen and patient population [7], [8], demanding new strategies to prevent the evolution of drug resistance and enhance the efficacy of antifungal drugs. The evolution of drug resistance is contingent on genetic variability, the ultimate source of which is mutation. One of the most fundamental questions of central importance to predicting and preventing the evolution of drug resistance is which mutations accompany the evolution of drug resistance in the human host. Developments in sequencing technology [9]–[11] now enable this question to be addressed on a genome-wide scale to reveal the identity of mutations that either confer drug resistance in a clinically relevant context or that modify the fitness consequences of resistance mutations. Whole genome sequencing has been applied to bacteria and has revealed principles underpinning the evolution and transmission of drug-resistant pathogens [12], risk factors for the evolution of drug resistance [13], and population dynamics during the evolution of drug resistance in vitro [14]. In fungi, changes in genome-wide gene expression and chromosomal alterations that accompany the evolution of drug resistance have been monitored in experimental populations that evolved resistance in vitro [15], [16], and targeted sequence and expression analysis of specific genes has been implemented to identify mechanisms of resistance that evolve in the human host [1], [17]. However, a global approach to mapping mutations that underpin the evolution of fungal drug resistance has yet to be achieved. Candida glabrata is a leading fungal pathogens of humans and provides a particularly powerful system for studying the evolution of drug resistance in a human host. Candida species are the fourth most common cause of hospital acquired blood-stream infections and are the most prevalent cause of invasive fungal infection worldwide, with mortality rates approaching 50% [7], [18]. C. glabrata is now second to C. albicans as the most prevalent Candida species isolated from clinical specimens [7], [8], [19]. This is due in part to both intrinsic and rapidly acquired resistance of C. glabrata to the azoles, which are the most widely used class of antifungal drugs and inhibit the biosynthesis of the key sterol in fungal cell membranes, ergosterol [20]. As a consequence, the echinocandins are the front-line therapeutic agent for C. glabrata infections [19]. C. glabrata is closely related to the model yeast Saccharomyces cerevisiae and is placed within the Saccharomyces clade rather than the Candida clade to which the leading cause of candidiasis, C. albicans, belongs [21]–[23]. It is thought that C. glabrata emerged as a human pathogen independently from other Candida species. Notably, gene families associated with pathogenicity in C. albicans including iron acquisition and host cell adhesion and invasion are absent from C. glabrata [24]. C. glabrata is an obligate haploid and mating has never been reported, although two mating types, mating type switching, and other mating and meiotic machinery have been described [25]–[27]. To increase genetic diversity C. glabrata undergoes chromosomal translocations and variation in gene copy number [28], [29], mechanisms that also contribute to C. albicans resistance to azoles [16], [30], [31]. As a haploid, analysis of C. glabrata genome sequence is more facile than in diploids such as C. albicans, where mitotic recombination and gene conversion can inflate the number of polymorphisms that accrue and obscure the signal of those functionally associated with drug resistance or adaptation to the host. Compared to the most widely used antifungal drugs in clinical use for the treatment of systemic infections, the azoles, mechanisms of resistance remain more limited for echinocandins. The echinocandins are the only novel class of antifungal drugs approved for clinical use in decades and target the biosynthesis of the key fungal cell wall component, 1,3-β-D-glucan [3], [20], [32]. The 1,3-β-D-glucan synthases are encoded by FKS1, FKS2, and FKS3 in S. cerevisiae, C. glabrata, and C. albicans, and require a regulatory subunit encoded by RHO1 for activity [3], [20], [32], [33]. It is thought that the echinocandins bind to and inhibit the Fks protein; however, the exact mechanism of inhibition remains unknown [33]. Although the echinocandins have been in clinical use since only 2001, there have been numerous reports of C. glabrata echinocandin resistance in patients [34]–[37]. Thus far, the only echinocandin resistance mechanism described is mutation in the drug target, Fks, particularly in highly conserved hot spots regions [33], [36]–[39]. Such mutations can reduce echinocandin susceptibility of 1,3-β-D-glucan synthase by 2 to 3 log orders relative to the wild-type enzyme [36]. Additional resistance mechanisms may remain to be described given that Fks mutations have not been identified in some echinocandin-resistant isolates [20], [37], [40], and that isolates with identical Fks mutations exhibit different resistance phenotypes with distinct responses to cellular perturbations [41]. Even with azoles, for which resistance mechanisms have been studied for decades, new resistance mechanisms and modulators of resistance continue to be discovered, expanding the repertoire of strategies employed by fungi to survive drug exposure to include mutation in the drug target, overexpression of multidrug-efflux transporters, and metabolic alterations that minimize drug toxicity [3], [20], [32]. In addition to these canonical resistance mechanisms where mutations in relevant genes confer resistance, there is also an emergent paradigm in which regulators of cellular stress responses are crucial for enabling the evolution and maintenance of drug resistance [3], [20], [32]; while mutations in these regulators have not been identified as a cause of resistance, stress response regulators are key resistance modulators critical for enabling the phenotypic effects of resistance acquired by diverse mechanisms. Beyond mapping mutations that confer resistance, there is pressing clinical need to elucidate strategies to block the evolution of drug resistance and abrogate resistance once it has evolved. One of the most well studied examples of a protein that governs the emergence and maintenance of fungal drug resistance is the molecular chaperone Hsp90. Hsp90 regulates the folding and function of diverse client proteins, including many signal transducers [42], [43]. In C. albicans, compromise of Hsp90 function reduces basal tolerance and resistance of clinical isolates to both the azoles and the echinocandins [41], [44], [45]. Hsp90 enables crucial responses to drug-induced stress by orchestrating signaling through the protein phosphatase calcineurin and the protein kinase C (PKC) cell wall integrity signaling cascade [41], [46]. Hsp90 stabilizes the catalytic subunit of calcineurin and the terminal mitogen-activated protein kinase (MAPK) in the Pkc1 cell wall integrity pathway. Genetic or pharmacological compromise of Hsp90 function can enhance the efficacy of antifungals against C. albicans in multiple metazoan models of infection [41], [45]. Notably, Hsp90's role in governing cellular responses to azoles in C. albicans is conserved in S. cerevisiae [44], [47]. In contrast, Hsp90 and calcineurin play a key role in crucial cellular responses to echinocandins in C. albicans, but not in S. cerevisiae [41]. Whether Hsp90 influences drug resistance in C. glabrata remains entirely unknown. In C. glabrata, both calcineurin and PKC signaling have been implicated in basal tolerance to echinocandins [48], [49], though the role of Hsp90 remains unknown as does the impact of any of these regulators on bona fide echinocandin resistance. Here, we provide the first global analysis of mutations accompanying the evolution of fungal drug resistance in a human host. We report on a series of C. glabrata isolates that evolved echinocandin resistance in a patient undergoing treatment with the echinocandin caspofungin for recurring C. glabrata candidemia over a 10-month period. Whole genome sequencing revealed that a mutation occurred in the gene encoding the drug target, FKS2, accompanying a major increase in resistance, as well as 8 other non-synonymous mutations in genes not previously implicated in echinocandin resistance, including CDC6 and CDC55. The FKS2-T1987C(S663P) mutation was sufficient to confer echinocandin resistance in a susceptible laboratory strain; however, the mutant allele also imparted a growth defect in clinically relevant conditions using RPMI medium at 37°C. The fitness cost of resistance was mitigated with further evolution, and this trend was also observed in a murine model of disseminated infection. A CDC6-A511G (K171E) mutation acquired prior to the FKS2-T1987C(S663P) mutation was sufficient to confer a small increase in resistance. Elevated dosage of CDC55, which acquired a C463T(P155S) mutation after FKS2-T1987C(S663P), ameliorated the fitness cost imparted by the FKS2 mutation. To uncover mechanisms that abrogate echinocandin resistance, we turned to Hsp90 and found that genetic or pharmacological compromise of C. glabrata Hsp90 function reduced basal tolerance and resistance of clinical isolates. Compromising calcineurin function pharmacologically or genetically phenocopied compromising Hsp90 function. Caspofungin induced FKS2 expression in a manner that depended upon Hsp90 and calcineurin, providing a molecular mechanism by which Hsp90 and calcineurin regulate echinocandin resistance. Furthermore, one of the clinical isolates in the series is a petite mutant based on morphology and inability to respire; although the petite phenotype was not intrinsically involved in echinocandin resistance, it imparted resistance to the combination of echinocandins and inhibitors of Hsp90 or calcineurin. In a mouse model of candidemia, the petite mutant was rapidly cleared and completely avirulent while infection with the HSP90-repressible strain yielded a reduced fungal burden compared to wild type. Thus, our results provide the first global view of mutations that accompany the evolution of fungal drug resistance in a human host, implicate the first compensatory mutation that mitigates the cost of echinocandin resistance, and suggest a new molecular mechanism regulating echinocandin resistance, with broad therapeutic potential.
What the sources say
- Disputedcites [33] DS Perlin, 2007, Resistance to echinocandin-class antifungal drugs., Drug Resist Updat sourceExperimental — accuracy not yet measured
Section 12 says Fks1 mutations are the only mechanism firmly associated with clinical echinocandin resistance, and sections 7–8 locate those mutations in conserved hot spots. But section 11 describes echinocandin-resistant fungi whose resistance indicates an alternative mechanism independent of Fks1. The claim's unqualified assertion that Fks mutation is the only described resistance mechanism is therefore contrary to the source. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
- Not matchedcites [36]–[39]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“In vitro biochemical studies established that this mutant Fks2 enzyme displays reduced sensitivity to inhibition by echinocandins, as indicated by a higher kinetic inhibition parameter, as well as decreased catalytic capacity, and reduced enzyme velocity, compared to the wild-type enzyme; notably the binding affinity of the mutant enzyme for echinocandins remains unchanged [36].”
§ Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata > Results > The FKS2 T1987C (S663P) mutation confers echinocandin resistance and imparts a fitness deficit in a C. glabrata laboratory strain To determine which of the mutations identified by whole genome sequencing contributes to echinocandin resistance we first turned to the most likely candidate resistance gene, FKS2. The FKS2 mutation that emerged in isolate D and was maintained throughout the rest of the series (T1987C) results in substitution of a serine to proline at amino acid 663 in the target of the echinocandins. This FKS2 T1987C (S663P) mutation has been previously associated with high levels of caspofungin resistance in C. glabrata clinical isolates [36], [37]. In vitro biochemical studies established that this mutant Fks2 enzyme displays reduced sensitivity to inhibition by echinocandins, as indicated by a higher kinetic inhibition parameter, as well as decreased catalytic capacity, and reduced enzyme velocity, compared to the wild-type enzyme; notably the binding affinity of the mutant enzyme for echinocandins remains unchanged [36]. While there is an association of FKS mutations with resistance, and biochemical data support the resistance mechanism, it has only been conclusively demonstrated that such mutations are sufficient to confer echinocandin resistance in S. cerevisiae [82], [83]. To test whether Fks2 S663P is sufficient to confer echinocandin resistance, we introduced the T1987C mutation into the sensitive laboratory strain BG2 using a strategy involving single-stranded DNA containing the mutation and a silent marker, followed by selection of transformants on medium containing caspofungin. No echinocandin-resistant colonies were obtained following control transformations with single-stranded DNA containing the equivalent wild-type sequence or with a water control, while many resistant colonies were obtained with the sequence containing the T1987C mutation. We assessed resistance of four sequence-verified transformants that harboured both the T1987C and silent mutation via minimum inhibitory concentration (MIC) assays. The transformants displayed resistance similar to clinical isolate G (Figure 2A). Thus, Fks2 S663P is sufficient to confer echinocandin resistance in a susceptible laboratory strain of C. glabrata. Given that specific Fks amino acid substitutions that decrease sensitivity of the 1,3-β-D-glucan synthase enzyme to echinocandins also reduce the enzyme catalytic capacity, the Fks2 S663P mutation may confer a fitness cost in terms of reduced growth or viability in the absence of the drug [36], [39]. To determine if the FKS2 mutations compromises fitness, we monitored growth kinetics of the lab strain BG2 and the progeny harbouring the Fks2 S663P substitution. In clinically relevant conditions, RPMI at 37°C, we found that strains harbouring the Fks2 S663P substitution displayed significantly reduced fitness relative to the parental wild-type laboratory strain BG2 (P<0.01, area under the curve followed by ANOVA, Bonferroni's Multiple Comparison Test, Figure 2B, left panel). Furthermore, we observed a significant reduction in fitness between isolate A and isolate D (P<0.001), which is rescued to some extent in isolate G (P<0.01, Figure 2B, right panel). Thus, the FKS2 mutation that emerged in clinical isolate D is sufficient to confer a high level of caspofungin resistance equivalent to that observed in the late isolate G, however, it is also associated with a cost in terms of reduced fitness in the absence of the drug.
What the sources say
- Supportedcites [36] G Garcia-Effron, 2009, Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint., Antimicrob Agents Chemother source
The Results state that mutant enzymes’ Km values were not statistically different from wild-type values and explicitly say the substitutions do not change the enzyme’s binding affinity for echinocandin drugs. The passage discusses Fks2p mutants among the enzymes studied. (LLM, conf=0.93)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In vitro biochemical studies established that this mutant Fks2 enzyme displays reduced sensitivity to inhibition by echinocandins, as indicated by a higher kinetic inhibition parameter, as well as decreased catalytic capacity, and reduced enzyme velocity, compared to the wild-type enzyme; notably the binding affinity of the mutant enzyme for echinocandins remains unchanged [36].”
§ Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata > Results > The FKS2 T1987C (S663P) mutation confers echinocandin resistance and imparts a fitness deficit in a C. glabrata laboratory strain To determine which of the mutations identified by whole genome sequencing contributes to echinocandin resistance we first turned to the most likely candidate resistance gene, FKS2. The FKS2 mutation that emerged in isolate D and was maintained throughout the rest of the series (T1987C) results in substitution of a serine to proline at amino acid 663 in the target of the echinocandins. This FKS2 T1987C (S663P) mutation has been previously associated with high levels of caspofungin resistance in C. glabrata clinical isolates [36], [37]. In vitro biochemical studies established that this mutant Fks2 enzyme displays reduced sensitivity to inhibition by echinocandins, as indicated by a higher kinetic inhibition parameter, as well as decreased catalytic capacity, and reduced enzyme velocity, compared to the wild-type enzyme; notably the binding affinity of the mutant enzyme for echinocandins remains unchanged [36]. While there is an association of FKS mutations with resistance, and biochemical data support the resistance mechanism, it has only been conclusively demonstrated that such mutations are sufficient to confer echinocandin resistance in S. cerevisiae [82], [83]. To test whether Fks2 S663P is sufficient to confer echinocandin resistance, we introduced the T1987C mutation into the sensitive laboratory strain BG2 using a strategy involving single-stranded DNA containing the mutation and a silent marker, followed by selection of transformants on medium containing caspofungin. No echinocandin-resistant colonies were obtained following control transformations with single-stranded DNA containing the equivalent wild-type sequence or with a water control, while many resistant colonies were obtained with the sequence containing the T1987C mutation. We assessed resistance of four sequence-verified transformants that harboured both the T1987C and silent mutation via minimum inhibitory concentration (MIC) assays. The transformants displayed resistance similar to clinical isolate G (Figure 2A). Thus, Fks2 S663P is sufficient to confer echinocandin resistance in a susceptible laboratory strain of C. glabrata. Given that specific Fks amino acid substitutions that decrease sensitivity of the 1,3-β-D-glucan synthase enzyme to echinocandins also reduce the enzyme catalytic capacity, the Fks2 S663P mutation may confer a fitness cost in terms of reduced growth or viability in the absence of the drug [36], [39]. To determine if the FKS2 mutations compromises fitness, we monitored growth kinetics of the lab strain BG2 and the progeny harbouring the Fks2 S663P substitution. In clinically relevant conditions, RPMI at 37°C, we found that strains harbouring the Fks2 S663P substitution displayed significantly reduced fitness relative to the parental wild-type laboratory strain BG2 (P<0.01, area under the curve followed by ANOVA, Bonferroni's Multiple Comparison Test, Figure 2B, left panel). Furthermore, we observed a significant reduction in fitness between isolate A and isolate D (P<0.001), which is rescued to some extent in isolate G (P<0.01, Figure 2B, right panel). Thus, the FKS2 mutation that emerged in clinical isolate D is sufficient to confer a high level of caspofungin resistance equivalent to that observed in the late isolate G, however, it is also associated with a cost in terms of reduced fitness in the absence of the drug.
What the sources say
- Supportedcites [36] G Garcia-Effron, 2009, Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint., Antimicrob Agents Chemother source
The Results (page not specified) report higher echinocandin IC50 values for mutant glucan synthase than for wild-type enzyme, indicating reduced sensitivity to inhibition. They specifically identify Fks2p substitutions among the mutants with elevated IC50 values. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This FKS2 T1987C (S663P) mutation has been previously associated with high levels of caspofungin resistance in C. glabrata clinical isolates [36], [37].”
§ Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata > Results > The FKS2 T1987C (S663P) mutation confers echinocandin resistance and imparts a fitness deficit in a C. glabrata laboratory strain To determine which of the mutations identified by whole genome sequencing contributes to echinocandin resistance we first turned to the most likely candidate resistance gene, FKS2. The FKS2 mutation that emerged in isolate D and was maintained throughout the rest of the series (T1987C) results in substitution of a serine to proline at amino acid 663 in the target of the echinocandins. This FKS2 T1987C (S663P) mutation has been previously associated with high levels of caspofungin resistance in C. glabrata clinical isolates [36], [37]. In vitro biochemical studies established that this mutant Fks2 enzyme displays reduced sensitivity to inhibition by echinocandins, as indicated by a higher kinetic inhibition parameter, as well as decreased catalytic capacity, and reduced enzyme velocity, compared to the wild-type enzyme; notably the binding affinity of the mutant enzyme for echinocandins remains unchanged [36]. While there is an association of FKS mutations with resistance, and biochemical data support the resistance mechanism, it has only been conclusively demonstrated that such mutations are sufficient to confer echinocandin resistance in S. cerevisiae [82], [83]. To test whether Fks2 S663P is sufficient to confer echinocandin resistance, we introduced the T1987C mutation into the sensitive laboratory strain BG2 using a strategy involving single-stranded DNA containing the mutation and a silent marker, followed by selection of transformants on medium containing caspofungin. No echinocandin-resistant colonies were obtained following control transformations with single-stranded DNA containing the equivalent wild-type sequence or with a water control, while many resistant colonies were obtained with the sequence containing the T1987C mutation. We assessed resistance of four sequence-verified transformants that harboured both the T1987C and silent mutation via minimum inhibitory concentration (MIC) assays. The transformants displayed resistance similar to clinical isolate G (Figure 2A). Thus, Fks2 S663P is sufficient to confer echinocandin resistance in a susceptible laboratory strain of C. glabrata. Given that specific Fks amino acid substitutions that decrease sensitivity of the 1,3-β-D-glucan synthase enzyme to echinocandins also reduce the enzyme catalytic capacity, the Fks2 S663P mutation may confer a fitness cost in terms of reduced growth or viability in the absence of the drug [36], [39]. To determine if the FKS2 mutations compromises fitness, we monitored growth kinetics of the lab strain BG2 and the progeny harbouring the Fks2 S663P substitution. In clinically relevant conditions, RPMI at 37°C, we found that strains harbouring the Fks2 S663P substitution displayed significantly reduced fitness relative to the parental wild-type laboratory strain BG2 (P<0.01, area under the curve followed by ANOVA, Bonferroni's Multiple Comparison Test, Figure 2B, left panel). Furthermore, we observed a significant reduction in fitness between isolate A and isolate D (P<0.001), which is rescued to some extent in isolate G (P<0.01, Figure 2B, right panel). Thus, the FKS2 mutation that emerged in clinical isolate D is sufficient to confer a high level of caspofungin resistance equivalent to that observed in the late isolate G, however, it is also associated with a cost in terms of reduced fitness in the absence of the drug.
What the sources say
- Supportedcites [36] G Garcia-Effron, 2009, Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint., Antimicrob Agents Chemother source
Results Table 1 identifies a clinical C. glabrata isolate with the FKS2 T1987C (S663P) mutation and reports a caspofungin MIC of 16 μg/ml, versus 0.06–0.12 μg/ml for wild-type isolates. Materials and Methods identifies the resistant strains as clinical isolates. (LLM, conf=0.94)
- Partly supportedcites [37] CD Pfeiffer, 2010, Breakthrough invasive candidiasis in patients on micafungin., J Clin Microbiol sourceExperimental — accuracy not yet measured
Table 2 (Results; page unavailable) identifies FKS2 S663P in C. glabrata clinical isolates with caspofungin MICs >16 μg/ml, supporting the association with high resistance. Our copy does not identify the underlying nucleotide change as T1987C, so that specific part is unverified. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The echinocandins are the only novel class of antifungal drugs approved for clinical use in decades and target the biosynthesis of the key fungal cell wall component, 1,3-β-D-glucan [3], [20], [32].”
§ Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata > Introduction The emergence of drug resistance is an evolutionary process with a profound impact on human health. The widespread deployment of antimicrobial agents in medicine and agriculture exerts strong selection for organisms with enhanced capacity to survive and reproduce in the presence of drug, which has led to the rapid emergence of drug resistance in diverse pathogen populations [1]–[4]. The evolution of drug resistance compromises the efficacy of drugs that we depend on critically for a myriad of therapeutic interventions, and has striking economic consequences. The annual cost attributable to the evolution of drug resistance in the United States alone exceeds $33 billion to cover treatment of patients with drug-resistant infections, additional pesticides required to manage resistant pests, and loss of crops to resistant pests [5]. The emergence of drug resistance in fungal pathogens is of particular concern given the increasing incidence of invasive fungal infections, and the limited number of antifungal drugs. Fungi can cause life-threatening infectious disease in immunocompromised hosts, as well as in healthy humans, and the incidence of fungal bloodstream infections has increased by 207% in recent decades [6]–[8]. Fungi are eukaryotes and share close evolutionary relationships with their human hosts, which limits the number of drug targets that can be exploited to selectively kill fungal pathogens yet minimize host toxicity [1], [3]. Even with current treatment options, mortality rates due to invasive fungal infections can reach 50–90% depending on the pathogen and patient population [7], [8], demanding new strategies to prevent the evolution of drug resistance and enhance the efficacy of antifungal drugs. The evolution of drug resistance is contingent on genetic variability, the ultimate source of which is mutation. One of the most fundamental questions of central importance to predicting and preventing the evolution of drug resistance is which mutations accompany the evolution of drug resistance in the human host. Developments in sequencing technology [9]–[11] now enable this question to be addressed on a genome-wide scale to reveal the identity of mutations that either confer drug resistance in a clinically relevant context or that modify the fitness consequences of resistance mutations. Whole genome sequencing has been applied to bacteria and has revealed principles underpinning the evolution and transmission of drug-resistant pathogens [12], risk factors for the evolution of drug resistance [13], and population dynamics during the evolution of drug resistance in vitro [14]. In fungi, changes in genome-wide gene expression and chromosomal alterations that accompany the evolution of drug resistance have been monitored in experimental populations that evolved resistance in vitro [15], [16], and targeted sequence and expression analysis of specific genes has been implemented to identify mechanisms of resistance that evolve in the human host [1], [17]. However, a global approach to mapping mutations that underpin the evolution of fungal drug resistance has yet to be achieved. Candida glabrata is a leading fungal pathogens of humans and provides a particularly powerful system for studying the evolution of drug resistance in a human host. Candida species are the fourth most common cause of hospital acquired blood-stream infections and are the most prevalent cause of invasive fungal infection worldwide, with mortality rates approaching 50% [7], [18]. C. glabrata is now second to C. albicans as the most prevalent Candida species isolated from clinical specimens [7], [8], [19]. This is due in part to both intrinsic and rapidly acquired resistance of C. glabrata to the azoles, which are the most widely used class of antifungal drugs and inhibit the biosynthesis of the key sterol in fungal cell membranes, ergosterol [20]. As a consequence, the echinocandins are the front-line therapeutic agent for C. glabrata infections [19]. C. glabrata is closely related to the model yeast Saccharomyces cerevisiae and is placed within the Saccharomyces clade rather than the Candida clade to which the leading cause of candidiasis, C. albicans, belongs [21]–[23]. It is thought that C. glabrata emerged as a human pathogen independently from other Candida species. Notably, gene families associated with pathogenicity in C. albicans including iron acquisition and host cell adhesion and invasion are absent from C. glabrata [24]. C. glabrata is an obligate haploid and mating has never been reported, although two mating types, mating type switching, and other mating and meiotic machinery have been described [25]–[27]. To increase genetic diversity C. glabrata undergoes chromosomal translocations and variation in gene copy number [28], [29], mechanisms that also contribute to C. albicans resistance to azoles [16], [30], [31]. As a haploid, analysis of C. glabrata genome sequence is more facile than in diploids such as C. albicans, where mitotic recombination and gene conversion can inflate the number of polymorphisms that accrue and obscure the signal of those functionally associated with drug resistance or adaptation to the host. Compared to the most widely used antifungal drugs in clinical use for the treatment of systemic infections, the azoles, mechanisms of resistance remain more limited for echinocandins. The echinocandins are the only novel class of antifungal drugs approved for clinical use in decades and target the biosynthesis of the key fungal cell wall component, 1,3-β-D-glucan [3], [20], [32]. The 1,3-β-D-glucan synthases are encoded by FKS1, FKS2, and FKS3 in S. cerevisiae, C. glabrata, and C. albicans, and require a regulatory subunit encoded by RHO1 for activity [3], [20], [32], [33]. It is thought that the echinocandins bind to and inhibit the Fks protein; however, the exact mechanism of inhibition remains unknown [33]. Although the echinocandins have been in clinical use since only 2001, there have been numerous reports of C. glabrata echinocandin resistance in patients [34]–[37]. Thus far, the only echinocandin resistance mechanism described is mutation in the drug target, Fks, particularly in highly conserved hot spots regions [33], [36]–[39]. Such mutations can reduce echinocandin susceptibility of 1,3-β-D-glucan synthase by 2 to 3 log orders relative to the wild-type enzyme [36]. Additional resistance mechanisms may remain to be described given that Fks mutations have not been identified in some echinocandin-resistant isolates [20], [37], [40], and that isolates with identical Fks mutations exhibit different resistance phenotypes with distinct responses to cellular perturbations [41]. Even with azoles, for which resistance mechanisms have been studied for decades, new resistance mechanisms and modulators of resistance continue to be discovered, expanding the repertoire of strategies employed by fungi to survive drug exposure to include mutation in the drug target, overexpression of multidrug-efflux transporters, and metabolic alterations that minimize drug toxicity [3], [20], [32]. In addition to these canonical resistance mechanisms where mutations in relevant genes confer resistance, there is also an emergent paradigm in which regulators of cellular stress responses are crucial for enabling the evolution and maintenance of drug resistance [3], [20], [32]; while mutations in these regulators have not been identified as a cause of resistance, stress response regulators are key resistance modulators critical for enabling the phenotypic effects of resistance acquired by diverse mechanisms. Beyond mapping mutations that confer resistance, there is pressing clinical need to elucidate strategies to block the evolution of drug resistance and abrogate resistance once it has evolved. One of the most well studied examples of a protein that governs the emergence and maintenance of fungal drug resistance is the molecular chaperone Hsp90. Hsp90 regulates the folding and function of diverse client proteins, including many signal transducers [42], [43]. In C. albicans, compromise of Hsp90 function reduces basal tolerance and resistance of clinical isolates to both the azoles and the echinocandins [41], [44], [45]. Hsp90 enables crucial responses to drug-induced stress by orchestrating signaling through the protein phosphatase calcineurin and the protein kinase C (PKC) cell wall integrity signaling cascade [41], [46]. Hsp90 stabilizes the catalytic subunit of calcineurin and the terminal mitogen-activated protein kinase (MAPK) in the Pkc1 cell wall integrity pathway. Genetic or pharmacological compromise of Hsp90 function can enhance the efficacy of antifungals against C. albicans in multiple metazoan models of infection [41], [45]. Notably, Hsp90's role in governing cellular responses to azoles in C. albicans is conserved in S. cerevisiae [44], [47]. In contrast, Hsp90 and calcineurin play a key role in crucial cellular responses to echinocandins in C. albicans, but not in S. cerevisiae [41]. Whether Hsp90 influences drug resistance in C. glabrata remains entirely unknown. In C. glabrata, both calcineurin and PKC signaling have been implicated in basal tolerance to echinocandins [48], [49], though the role of Hsp90 remains unknown as does the impact of any of these regulators on bona fide echinocandin resistance. Here, we provide the first global analysis of mutations accompanying the evolution of fungal drug resistance in a human host. We report on a series of C. glabrata isolates that evolved echinocandin resistance in a patient undergoing treatment with the echinocandin caspofungin for recurring C. glabrata candidemia over a 10-month period. Whole genome sequencing revealed that a mutation occurred in the gene encoding the drug target, FKS2, accompanying a major increase in resistance, as well as 8 other non-synonymous mutations in genes not previously implicated in echinocandin resistance, including CDC6 and CDC55. The FKS2-T1987C(S663P) mutation was sufficient to confer echinocandin resistance in a susceptible laboratory strain; however, the mutant allele also imparted a growth defect in clinically relevant conditions using RPMI medium at 37°C. The fitness cost of resistance was mitigated with further evolution, and this trend was also observed in a murine model of disseminated infection. A CDC6-A511G (K171E) mutation acquired prior to the FKS2-T1987C(S663P) mutation was sufficient to confer a small increase in resistance. Elevated dosage of CDC55, which acquired a C463T(P155S) mutation after FKS2-T1987C(S663P), ameliorated the fitness cost imparted by the FKS2 mutation. To uncover mechanisms that abrogate echinocandin resistance, we turned to Hsp90 and found that genetic or pharmacological compromise of C. glabrata Hsp90 function reduced basal tolerance and resistance of clinical isolates. Compromising calcineurin function pharmacologically or genetically phenocopied compromising Hsp90 function. Caspofungin induced FKS2 expression in a manner that depended upon Hsp90 and calcineurin, providing a molecular mechanism by which Hsp90 and calcineurin regulate echinocandin resistance. Furthermore, one of the clinical isolates in the series is a petite mutant based on morphology and inability to respire; although the petite phenotype was not intrinsically involved in echinocandin resistance, it imparted resistance to the combination of echinocandins and inhibitors of Hsp90 or calcineurin. In a mouse model of candidemia, the petite mutant was rapidly cleared and completely avirulent while infection with the HSP90-repressible strain yielded a reduced fungal burden compared to wild type. Thus, our results provide the first global view of mutations that accompany the evolution of fungal drug resistance in a human host, implicate the first compensatory mutation that mitigates the cost of echinocandin resistance, and suggest a new molecular mechanism regulating echinocandin resistance, with broad therapeutic potential.
What the sources say
- Not checked — no full text of the sourcecites [3] LE Cowen, 2008, The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype., Nat Rev Microbiol source
- Supportedcites [20] RS Shapiro, 2011, Regulatory circuitry governing fungal development, drug resistance, and disease., Microbiol Mol Biol Rev source
The Echinocandins subsection states that echinocandins inhibit (1,3)-β-D-glucan synthase, an enzyme involved in fungal cell wall synthesis. This directly supports the attributed claim about their target. (LLM, conf=0.95)
- Supportedcites [32] LE Cowen, 2008, Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance., Eukaryot Cell source
The ‘ANTIFUNGAL DRUGS AND CLINICAL ANTIFUNGAL RESISTANCE’ section states that echinocandins inhibit (1,3)-β-D-glucan synthase, interfering with biosynthesis of an essential fungal cell-wall polysaccharide. The ‘RESISTANCE TO DRUGS EXERTING CELL WALL STRESS’ section also says they inhibit synthesis of (1,3)-β-D-glucan. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
124 more claims · 11 with their cited sources checked
Create a free account to see all 187 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 39
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to genetic determinants of tolerance level, growth conditions influence the degree of tolerance exhibited by a strain.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas calcineurin inhibitors reduce echinocandin tolerance (measured using MIC assays analyzed after 72 h)68,78.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While its role in drug tolerance, persistence, and stable resistance is documented [19, 20, 21, 22]”
From Calcineurin‐Dependent Stress Adaptation Enables Caspofungin Heteroresistance Leading to Stable Resistance in Candida Glabrata (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, ECN resistance can develop quickly upon the onset of ECN treatment (73, 74).”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Antifungal drug resistance is most likely accompanied by trade-offs in fungal fitness in certain environments such as the absence of antifungal selection pressure (74, 87, 88).”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [74]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The epidemiology of sepsis in the United States from 1979 through 2000
Martin, G. S., Mannino, D. M., Eaton, S., & Moss, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022139 · Cited by 5,841
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Global analysis of protein localization in budding yeast
Huh, W.-K., Falvo, J. V., Gerke, L. C., Carroll, A. S., Howson, R. W., Weissman, J. S., & O'Shea, E. K. (2003) · Nature · doi:10.1038/nature02026 · Cited by 4,248
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 3×
“infections can reach 50–90% depending on the pathogen and patient population [7,8], demanding new strategies to prevent the evolution of drug resistance and enhance the efficacy of antifungal drugs.”
BackgroundNext-Generation DNA Sequencing Methods
Mardis, E. R. (2008) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.9.081307.164359 · Cited by 2,369 · cited 1×
“Developments in sequencing technology [9–11] now enable this question to be addressed on a genome-wide scale to reveal the identity of mutations that either confer drug resistance in a clinically relevant context or that modify the fitness consequences of resistance mutations.”
BackgroundAntibiotic resistance and its cost: is it possible to reverse resistance?
Andersson, D. I., & Hughes, D. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2319 · Cited by 2,294 · cited 1×
“The fitness effects of antibiotic resistance mutations have been studied extensively in bacteria, where most resistance mechanisms are associated with a fitness cost that manifests in reduced growth rate [84].”
BackgroundHSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
Dujon, B., Sherman, D., Fischer, G., Durrens, P., Casaregola, S., Lafontaine, I., de Montigny, J., Marck, C., Neuvéglise, C., Talla, E., et al. (2004) · Nature · doi:10.1038/nature02579 · Cited by 1,623 · cited 1×
“cerevisiae with a large number of orthologs between the two species, facilitating bioinformatic analysis [21,22].”
BackgroundWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Humans as the World's Greatest Evolutionary Force
Palumbi, S. R. (2001) · Science · doi:10.1126/science.293.5536.1786 · Cited by 1,290 · cited 1×
“pests [5].”
Evolution of MRSA During Hospital Transmission and Intercontinental Spread
Harris, S. R., Feil, E. J., Holden, M. T. G., Quail, M. A., Nickerson, E. K., Chantratita, N., Gardete, S., Tavares, A., Day, N., Lindsay, J. A., et al. (2010) · Science · doi:10.1126/science.1182395 · Cited by 1,091
Evolution of pathogenicity and sexual reproduction in eight Candida genomes
Butler, G., Rasmussen, M. D., Lin, M. F., Santos, M. A. S., Sakthikumar, S., Munro, C. A., Rheinbay, E., Grabherr, M., Forche, A., Reedy, J. L., et al. (2009) · Nature · doi:10.1038/nature08064 · Cited by 1,065
Self-citationRoe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953
An integrated model of the recognition of Candida albicans by the innate immune system
Netea, M. G., Brown, G. D., Kullberg, B. J., & Gow, N. A. R. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1815 · Cited by 946
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Zaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784 · cited 1×
“Candida species are the fourth most common cause of hospital acquired blood-stream infections and are the most prevalent cause of invasive fungal infection worldwide, with mortality rates approaching 50% [7,18].”
BackgroundAneuploidy and Isochromosome Formation in Drug-Resistant Candida albicans
Selmecki, A., Forche, A., & Berman, J. (2006) · Science · doi:10.1126/science.1128242 · Cited by 733
Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi
Cowen, L. E., & Lindquist, S. (2005) · Science · doi:10.1126/science.1118370 · Cited by 698
Self-citationHigh‐throughput DNA sequencing – concepts and limitations
Kircher, M., & Kelso, J. (2010) · BioEssays · doi:10.1002/bies.200900181 · Cited by 671 · cited 1×
“Supporting their clinical relevance, Hsp90 inhibitors have advanced in clinical trials for the treatment of cancer and other diseases [9,127,128], and calcineurin inhibitors are widely used in the clinic as immunosuppressants [92].”
BackgroundBacterial charity work leads to population-wide resistance
Lee, H. H., Molla, M. N., Cantor, C. R., & Collins, J. J. (2010) · Nature · doi:10.1038/nature09354 · Cited by 638
Levin, B. R., Perrot, V., & Walker, N. (2000) · Genetics · doi:10.1093/genetics/154.3.985 · Cited by 624
Genetic control of Candida albicans biofilm development
Finkel, J. S., & Mitchell, A. P. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2475 · Cited by 612 · cited 2×
“infections can reach 50–90% depending on the pathogen and patient population [7,8], demanding new strategies to prevent the evolution of drug resistance and enhance the efficacy of antifungal drugs.”
BackgroundWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Regulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576 · cited 8×
“Additional resistance mechanisms may remain to be described given that Fks mutations have not been identified in some echinocandin-resistant isolates [20,37,40], and that isolates with identical Fks mutations exhibit different resistance phenotypes with distinct responses to cellular perturbations [41].”
BackgroundMethodInfluentialSelf-citationWandinger, S. K., Richter, K., & Buchner, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800007200 · Cited by 546 · cited 1×
“function of diverse client proteins, including many signal transducers [42,43].”
BackgroundResistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512 · cited 2×
“albicans, and require a regulatory subunit encoded by RHO1 for activity [3,20,32,33].”
BackgroundA fungal phylogeny based on 42 complete genomes derived from supertree and combined gene analysis.
(2006) · BMC Evolutionary Biology · doi:10.1186/1471-2148-6-99 · Cited by 475
Diverse Cellular Functions of the Hsp90 Molecular Chaperone Uncovered Using Systems Approaches
McClellan, A. J., Xia, Y., Deutschbauer, A. M., Davis, R. W., Gerstein, M., & Frydman, J. (2007) · Cell · doi:10.1016/j.cell.2007.07.036 · Cited by 474
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470
Identification of High-Copy Disruptors of Telomeric Silencing in Saccharomyces cerevisiae
Singer, M. S., Kahana, A., Wolf, A. J., Meisinger, L. L., Peterson, S. E., Goggin, C., Mahowald, M., & Gottschling, D. E. (1998) · Genetics · doi:10.1093/genetics/150.2.613 · Cited by 467
Ford, C. B., Lin, P. L., Chase, M. R., Shah, R. R., Iartchouk, O., Galagan, J., Mohaideen, N., Ioerger, T. R., Sacchettini, J. C., Lipsitch, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.811 · Cited by 437
Differential Expression and Function of Two Homologous Subunits of Yeast 1,3-β-D-Glucan Synthase
Mazur, P., Morin, N., Baginsky, W., el-Sherbeini, M., Clemas, J. A., Nielsen, J. B., & Foor, F. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5671 · Cited by 424
Cowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813394106 · Cited by 413
Self-citationDouglas, C. M., Foor, F., Marrinan, J. A., Morin, N., Nielsen, J. B., Dahl, A. M., Mazur, P., Baginsky, W., Li, W., & el-Sherbeini, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12907 · Cited by 401
High-resolution DNA-binding specificity analysis of yeast transcription factors
Zhu, C., Byers, K. J. R. P., McCord, R. P., Shi, Z., Berger, M. F., Newburger, D. E., Saulrieta, K., Smith, Z., Shah, M. V., Radhakrishnan, M., et al. (2009) · Genome Research · doi:10.1101/gr.090233.108 · Cited by 398
Evolution of antifungal-drug resistance: mechanisms and pathogen fitness
Anderson, J. B. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1179 · Cited by 375 · cited 2×
“In fungi, changes in genome-wide gene expression and chromosomal alterations that accompany the evolution of drug resistance have been monitored in experimental populations that evolved resistance in vitro [15,16], and targeted sequence and expression analysis of specific genes has been implemented to identify mechani…”
BackgroundHsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000532 · Cited by 362
Self-citationAn essential role for the Cdc6 protein in forming the pre-replicative complexes of budding yeast
Cocker, J. H., Piatti, S., Santocanale, C., Nasmyth, K., & Diffley, J. F. X. (1996) · Nature · doi:10.1038/379180a0 · Cited by 354
LaFayette, S. L., Collins, C., Zaas, A. K., Schell, W. A., Betancourt-Quiroz, M., Gunatilaka, A. A. L., Perfect, J. R., & Cowen, L. E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001069 · Cited by 329
Self-citationAn isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1
Selmecki, A., Gerami‐Nejad, M., Paulson, C., Forche, A., & Berman, J. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06176.x · Cited by 325
Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323
Selmecki, A. M., Dulmage, K., Cowen, L. E., Anderson, J. B., & Berman, J. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000705 · Cited by 319 · cited 1×
“In fungi, changes in genome-wide gene expression and chromosomal alterations that accompany the evolution of drug resistance have been monitored in experimental populations that evolved resistance in vitro [15,16], and targeted sequence and expression analysis of specific genes has been implemented to identify mechani…”
BackgroundSelf-citationHarnessing calcineurin as a novel anti-infective agent against invasive fungal infections.
Steinbach, W. J., Reedy, J. L., Cramer, R. A., Perfect, J. R., & Heitman, J. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1680 · Cited by 313
Fungal ß(1,3)-D-glucan synthesis
Douglas, C. M. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.55.66 · Cited by 312
Hsp90 Orchestrates Temperature-Dependent Candida albicans Morphogenesis via Ras1-PKA Signaling
Shapiro, R. S., Uppuluri, P., Zaas, A. K., Collins, C., Senn, H., Perfect, J. R., Heitman, J., & Cowen, L. E. (2009) · Current Biology · doi:10.1016/j.cub.2009.03.017 · Cited by 311
Self-citationThe evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype.
Cowen, L. E. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1835 · Cited by 311
Self-citationUpdate on Hsp90 Inhibitors in Clinical Trial
Kim, Y., Alarcon, S., Lee, S., Lee, M.-J., Giaccone, G., Neckers, L., & Trepel, J. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789895728 · Cited by 311
Genotypic Evolution of Azole Resistance Mechanisms in Sequential Candida albicans Isolates
Coste, A., Selmecki, A., Forche, A., Diogo, D., Bougnoux, M.-E., d'Enfert, C., Berman, J., & Sanglard, D. (2007) · Eukaryotic Cell · doi:10.1128/ec.00151-07 · Cited by 305
Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms
Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez-Ribot, J. L., Andes, D., & Cowen, L. E. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002257 · Cited by 291
Self-citationStress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285 · cited 4×
“albicans, and require a regulatory subunit encoded by RHO1 for activity [3,20,32,33].”
BackgroundInfluentialSelf-citationHealy, A. M., Zolnierowicz, S., Stapleton, A. E., Goebl, M., DePaoli-Roach, A. A., & Pringle, J. R. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.11.5767 · Cited by 284
Dunkel, N., Blaß, J., Rogers, P. D., & Morschhäuser, J. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06309.x · Cited by 278
Garcia-Effron, G., Park, S., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01162-08 · Cited by 256
Sanglard, D., Ischer, F., & Bille, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1174-1183.2001 · Cited by 247
Downregulation of PP2ACdc55 Phosphatase by Separase Initiates Mitotic Exit in Budding Yeast
Queralt, E., Lehane, C., Novak, B., & Uhlmann, F. (2006) · Cell · doi:10.1016/j.cell.2006.03.038 · Cited by 240
Population Biology, Evolution, and Infectious Disease: Convergence and Synthesis
Levin, B. R., Lipsitch, M., & Bonhoeffer, S. (1999) · Science · doi:10.1126/science.283.5403.806 · Cited by 234 · cited 1×
“tions [1–4].”
Synergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms
Uppuluri, P., Nett, J., Heitman, J., & Andes, D. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01397-07 · Cited by 228
Self-citationCalcineurin: Structure, function, and inhibition
Hemenway, C. S., & Heitman, J. (1999) · Cell Biochemistry and Biophysics · doi:10.1007/bf02737887 · Cited by 227
Self-citationBalashov, S. V., Park, S., & Perlin, D. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-05 · Cited by 225
Zhao, C., Jung, U. S., Garrett-Engele, P., Roe, T., Cyert, M. S., & Levin, D. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.1013 · Cited by 209
Evolution of Drug Resistance in Experimental Populations of Candida albicans
Cowen, L. E., Sanglard, D., Calabrese, D., Sirjusingh, C., Anderson, J. B., & Kohn, L. M. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.6.1515-1522.2000 · Cited by 207
Self-citationFormation of new chromosomes as a virulence mechanism in yeast Candida glabrata
Poláková, S., Blume, C., Zárate, J. Á., Mentel, M., Jørck-Ramberg, D., Stenderup, J., & Piškur, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809793106 · Cited by 206 · cited 1×
“glabrata undergoes chromosomal translocations and variation in gene copy number [28,29], mechanisms that also contribute to C.”
BackgroundCharacterization and Gene Cloning of 1,3-beta-D-Glucan Synthase from Saccharomyces Cerevisiae
Inoue, S. B., Takewakt, N., Takasuka, T., Mio, T., Adachi, M., Fujii, Y., Miyamoto, C., Arisawa, M., Furuichi, Y., & Watanabe, T. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.0845d.x · Cited by 201
An Extensive Circuitry for Cell Wall Regulation in Candida albicans
Blankenship, J. R., Fanning, S., Hamaker, J. J., & Mitchell, A. P. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000752 · Cited by 201
Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S., & Alexander, B. D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02390-09 · Cited by 196 · cited 2×
“Additional resistance mechanisms may remain to be described given that Fks mutations have not been identified in some echinocandin-resistant isolates [20,37,40], and that isolates with identical Fks mutations exhibit different resistance phenotypes with distinct responses to cellular perturbations [41].”
BackgroundKatiyar, S., Pfaller, M., & Edlind, T. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00349-06 · Cited by 189
Compensation of Fitness Costs and Reversibility of Antibiotic Resistance Mutations
Schulz zur Wiesch, P., Engelstädter, J., & Bonhoeffer, S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01460-09 · Cited by 169
Heat Shock Protein 90 as a Drug Target against Protozoan Infections
Pallavi, R., Roy, N., Nageshan, R. K., Talukdar, P., Pavithra, S. R., Reddy, R., Venketesh, S., Kumar, R., Gupta, A. K., Singh, R. K., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.155317 · Cited by 168
Lorenz, M. C., & Heitman, J. (1998) · Genetics · doi:10.1093/genetics/150.4.1443 · Cited by 167
Self-citationLesage, G., Sdicu, A.-M., Ménard, P., Shapiro, J., Hussein, S., & Bussey, H. (2004) · Genetics · doi:10.1534/genetics.167.1.35 · Cited by 166
Martinez, M. J., Roy, S., Archuletta, A. B., Wentzell, P. D., Anna-Arriola, S. S., Rodriguez, A. L., Aragon, A. D., Quiñones, G. A., Allen, C., & Werner-Washburne, M. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-11-0856 · Cited by 164
Global Survey of Genomic Imprinting by Transcriptome Sequencing
Babak, T., DeVeale, B., Armour, C., Raymond, C., Cleary, M. A., van der Kooy, D., Johnson, J. M., & Lim, L. P. (2008) · Current Biology · doi:10.1016/j.cub.2008.09.044 · Cited by 163 · cited 1×
“. Single nucleotide variants were identified using a machine learning approach as described previously”
MethodSelf-citationHernandez, S., López-Ribot, J. L., Najvar, L. K., McCarthy, D. I., Bocanegra, R., & Graybill, J. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1382-1383.2004 · Cited by 162 · cited 1×
“The most detailed sampling includes a clinical isolate pre-caspofungin treatment and two isolates taken serially post-caspofungin treatment, however, the mechanism by which resistance evolved was not investigated [50].”
BackgroundGenetic Architecture of Hsp90-Dependent Drug Resistance
Cowen, L. E., Carpenter, A. E., Matangkasombut, O., Fink, G. R., & Lindquist, S. (2006) · Eukaryotic Cell · doi:10.1128/ec.00274-06 · Cited by 159
Self-citationMechanisms of Azole Resistance in Petite Mutants of Candida glabrata
Brun, S., Bergès, T., Poupard, P., Vauzelle-Moreau, C., Renier, G., Chabasse, D., & Bouchara, J.-P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1788-1796.2004 · Cited by 151
Evolution of Drug Resistance in Candida Albicans
Cowen, L. E., Anderson, J. B., & Kohn, L. M. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160907 · Cited by 151 · cited 1×
“In fungi, changes in genome-wide gene expression and chromosomal alterations that accompany the evolution of drug resistance have been monitored in experimental populations that evolved resistance in vitro [15,16], and targeted sequence and expression analysis of specific genes has been implemented to identify mechani…”
BackgroundSelf-citationBonhomme, J., Chauvel, M., Goyard, S., Roux, P., Rossignol, T., & d'Enfert, C. (2011) · Molecular Microbiology · doi:10.1111/j.1365-2958.2011.07626.x · Cited by 144
Ferrari, S., Sanguinetti, M., De Bernardis, F., Torelli, R., Posteraro, B., Vandeputte, P., & Sanglard, D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01271-10 · Cited by 144
Nowrousian, M. (2010) · Eukaryotic Cell · doi:10.1128/ec.00123-10 · Cited by 142 · cited 1×
“Developments in sequencing technology [9–11] now enable this question to be addressed on a genome-wide scale to reveal the identity of mutations that either confer drug resistance in a clinically relevant context or that modify the fitness consequences of resistance mutations.”
BackgroundPopulation genomics of drug resistance in Candida albicans
Cowen, L. E., Nantel, A., Whiteway, M. S., Thomas, D. Y., Tessier, D. C., Kohn, L. M., & Anderson, J. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102291099 · Cited by 140 · cited 2×
“In fungi, changes in genome-wide gene expression and chromosomal alterations that accompany the evolution of drug resistance have been monitored in experimental populations that evolved resistance in vitro [15,16], and targeted sequence and expression analysis of specific genes has been implemented to identify mechani…”
BackgroundSelf-citationZimbeck, A. J., Iqbal, N., Ahlquist, A. M., Farley, M. M., Harrison, L. H., Chiller, T., & Lockhart, S. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00836-10 · Cited by 136
Niimi, K., Maki, K., Ikeda, F., Holmes, A. R., Lamping, E., Niimi, M., Monk, B. C., & Cannon, R. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1148-1155.2006 · Cited by 134
Characterization and Gene Cloning of 1,3-beta-D-Glucan Synthase from Saccharomyces Cerevisiae
Inoue, S., Takewakt, N., Takasuka, T., et al. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20770.x · Cited by 134
Sherman, D. J., Martin, T., Nikolski, M., Cayla, C., Souciet, J.-L., & Durrens, P. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn859 · Cited by 129
Wang, Y., & Burke, D. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.2.620 · Cited by 128
Dagley, M. J., Gentle, I. E., Beilharz, T. H., Pettolino, F. A., Djordjevic, J. T., Lo, T. L., Uwamahoro, N., Rupasinghe, T., Tull, D. L., McConville, M., et al. (2011) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07503.x · Cited by 128
Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains
Castanheira, M., Woosley, L. N., Diekema, D. J., Messer, S. A., Jones, R. N., & Pfaller, M. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01711-09 · Cited by 125
Role of HSP90 in salt stress tolerance via stabilization and regulation of calcineurin.
Imai, J., & Yahara, I. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.24.9262-9270.2000 · Cited by 123
Cleary, J. D., Garcia-Effron, G., Chapman, S. W., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-07 · Cited by 118
Bachmann, S. P., Patterson, T. F., & López-Ribot, J. L. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.6.2228-2230.2002 · Cited by 117
Cowen, L. E., Kohn, L. M., & Anderson, J. B. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.10.2971-2978.2001 · Cited by 113
Self-citationCopping, V. M. S., Barelle, C. J., Hube, B., Gow, N. A. R., Brown, A. J. P., & Odds, F. C. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki088 · Cited by 113
Hoot, S. J., Smith, A. R., Brown, R. P., & White, T. C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00995-10 · Cited by 107
Schuetzer‐Muehlbauer, M., Willinger, B., Egner, R., Ecker, G., & Kuchler, K. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(03)00213-9 · Cited by 103
Ashrafi, K., Farazi, T. A., & Gordon, J. I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25864 · Cited by 95
Molecular analysis of GPH1, the gene encoding glycogen phosphorylase in Saccharomyces cerevisiae.
Hwang, P. K., Tugendreich, S., & Fletterick, R. J. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.4.1659 · Cited by 92
Shahinas, D., Liang, M., Datti, A., & Pillai, D. R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901796s · Cited by 91
Butler, G. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00053-09 · Cited by 88
In-vivo selection of an azole-resistant petite mutant of Candida glabrata
BOUCHARA, J.-P., LE BOUDOUIL, S., FILMON, R., ZOUHAIR, R., HALLET, J.-N., CHABASSE, D., RENIER, G., & DEFONTAINE, A. (2000) · Journal of Medical Microbiology · doi:10.1099/0022-1317-49-11-977 · Cited by 88
Roles of Calcineurin and Crz1 in Antifungal Susceptibility and Virulence of Candida glabrata
Miyazaki, T., Yamauchi, S., Inamine, T., Nagayoshi, Y., Saijo, T., Izumikawa, K., Seki, M., Kakeya, H., Yamamoto, Y., Yanagihara, K., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01364-09 · Cited by 88
Rodaki, A., Young, T., & Brown, A. J. P. (2006) · Eukaryotic Cell · doi:10.1128/ec.00115-06 · Cited by 84
Marcet-Houben, M., & Gabaldón, T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004357 · Cited by 83 · cited 1×
“cerevisiae with a large number of orthologs between the two species, facilitating bioinformatic analysis [21,22].”
BackgroundMNL1 Regulates Weak Acid–induced Stress Responses of the Fungal Pathogen Candida albicans
Ramsdale, M., Selway, L., Stead, D., Walker, J., Yin, Z., Nicholls, S. M., Crowe, J., Sheils, E. M., & Brown, A. J. P. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-09-0946 · Cited by 79
Muller, H., Thierry, A., Coppée, J.-Y., Gouyette, C., Hennequin, C., Sismeiro, O., Talla, E., Dujon, B., & Fairhead, C. (2009) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2008.11.006 · Cited by 78
Evolution by Any Other Name: Antibiotic Resistance and Avoidance of the E-Word
Antonovics, J., Abbate, J. L., Baker, C. H., Daley, D., Hood, M. E., Jenkins, C. E., Johnson, L. J., Murray, J. J., Panjeti, V., Rudolf, V. H. W., et al. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050030 · Cited by 78
Phenotypic Switching and Mating Type Switching of Candida glabrata at Sites ofColonization
Brockert, P. J., Lachke, S. A., Srikantha, T., Pujol, C., Galask, R., & Soll, D. R. (2003) · Infection and Immunity · doi:10.1128/iai.71.12.7109-7118.2003 · Cited by 75
The role of nutrient regulation and the Gpa2 protein in the mating pheromone response of C. albicans
Bennett, R. J., & Johnson, A. D. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05367.x · Cited by 74
Kumar, R., Musiyenko, A., & Barik, S. (2005) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2005.01.012 · Cited by 71
Kontoyiannis, D. P. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.191 · Cited by 70
Miyazaki, T., Inamine, T., Yamauchi, S., Nagayoshi, Y., Saijo, T., Izumikawa, K., Seki, M., Kakeya, H., Yamamoto, Y., Yanagihara, K., et al. (2010) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2010.00611.x · Cited by 70
Laurino, J. P., Thompson, G. M., Pacheco, E., & Castilho, B. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.173 · Cited by 70
Biological consequences of petite mutations in Candida glabrata
Brun, S., Dalle, F., Saulnier, P., Renier, G., Bonnin, A., Chabasse, D., & Bouchara, J.-P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki200 · Cited by 65
Schulz, T., Creutz, C. E., & Snyder, S. L. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4029-8 · Cited by 64
Lin, C.-Y., Chen, Y.-C., Lo, H.-J., Chen, K.-W., & Li, S.-Y. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00699-07 · Cited by 62
Self-citationCheng, S., Clancy, C. J., Nguyen, K. T., Clapp, W., & Nguyen, M. H. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00182-07 · Cited by 62
Cdc6p establishes and maintains a state of replication competence during G1 phase
Detweiler, C. S., & Li, J. (1997) · Journal of Cell Science · doi:10.1242/jcs.110.6.753 · Cited by 60
Marchetti, O., Moreillon, P., Entenza, J. M., Vouillamoz, J., Glauser, M. P., Bille, J., & Sanglard, D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1565-1570.2003 · Cited by 58
Chen, K.-W., Lo, H.-J., Lin, Y.-H., & Li, S.-Y. (2005) · Journal of Medical Microbiology · doi:10.1099/jmm.0.45829-0 · Cited by 57
Sunnarborg, S. W., Miller, S. P., Unnikrishnan, I., & LaPorte, D. C. (2001) · Yeast · doi:10.1002/yea.752 · Cited by 53
Naderer, T., Dandash, O., & McConville, M. J. (2011) · Molecular Microbiology · doi:10.1111/j.1365-2958.2011.07584.x · Cited by 47
Chen, Y.-L., Kauffman, S., & Reynolds, T. B. (2008) · Infection and Immunity · doi:10.1128/iai.01514-07 · Cited by 47
Self-citationBorah, S., Shivarathri, R., & Kaur, R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.264671 · Cited by 44
Kitakawa, M., Graack, H., Grohmann, L., Goldschmidt‐Reisin, S., Herfurth, E., Wittmann‐Liebold, B., Nishimura, T., & Isono, K. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00449.x · Cited by 42
Ben-Ami, R., & Kontoyiannis, D. P. (2012) · Virulence · doi:10.4161/viru.3.1.18886 · Cited by 39
Onyewu, C., Afshari, N. A., & Heitman, J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00393-06 · Cited by 36
Self-citation(2009) · Springer eBooks · doi:10.1007/978-0-387-78665-0_6378 · Cited by 34
Cdc55 coordinates spindle assembly and chromosome disjunction during meiosis
Bizzari, F., & Marston, A. L. (2011) · The Journal of Cell Biology · doi:10.1083/jcb.201103076 · Cited by 28
Tanaka, M. M., & Valckenborgh, F. (2011) · Evolution · doi:10.1111/j.1558-5646.2011.01223.x · Cited by 28
Posteraro, B. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl237 · Cited by 27
Strategies for Stalling Malignancy: Targeting Cancers Addiction to Hsp90
Prodromou, C. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789895656 · Cited by 25
The yeast ORF YDL202w codes for the mitochondrial ribosomal protein YmL11
Minh, D. B., Jarosch, E., & Schweyen, R. J. (1997) · Current Genetics · doi:10.1007/s002940050221 · Cited by 5
Research works printed but not linked: 1
- 2008, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard, Third Edition, Document M27-A3
Cited by
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Self-citationDrug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
“Inhibition of Hsp90 reduces echinocandin resistance acquired by mutation in the drug target, and resistance that evolved in the human host (Singh et al. 2009; Singh-Babak et al. 2012).”
BackgroundInfluentialSelf-citationAntifungal drug resistance: evolution, mechanisms and impact
Revie, N. M., Iyer, K. R., Robbins, N., & Cowen, L. E. (2018) · Current Opinion in Microbiology · doi:10.1016/j.mib.2018.02.005 · Cited by 516
Self-citationMolecular Evolution of Antifungal Drug Resistance
Robbins, N., Caplan, T., & Cowen, L. E. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-030117-020345 · Cited by 441
Self-citation
Metadata
- Authors
- Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E.
- Affiliations
- University of Toronto (CA)
- Stanford University (US)
- Duke Medical Center (US)
- Mount Sinai Hospital (CA)
- University of Alberta (CA)
- Corresponding author
- Cowen, Leah E.
- ORCID
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-05-17
- Volume
- 8
- Issue
- 5
- Pages
- e1002718
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC3355103
- OpenAlex
- W2019892034
- Cited by
- 205
- References
- 133
- Citations by year
- 2026: 15 · 2025: 15 · 2024: 10 · 2023: 11 · 2022: 11 · 2021: 15 · 2020: 15 · 2019: 14 · 2018: 22 · 2017: 16 · 2016: 14 · 2015: 18 · 2014: 22 · 2013: 4 · 2012: 3
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure (University of Bath) (publishedVersion, cc-by)
- Bristol Research (University of Bristol) (publishedVersion)
- The University of Bath Online Publications Store (The University of Bath) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Explore Bristol Research (submittedVersion)
- Funders
- Burroughs Wellcome Fund
- University of Toronto
- National Institutes of Health
- Center for AIDS Research, Duke University (AI 064518)
- Center for AIDS Research, University of Washington
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada (355965-2009)
- National Institute of Allergy and Infectious Diseases (R01AI050438, P30AI064518)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- echinocandin resistance, Candida glabrata, caspofungin, FKS2, CDC6, Cdc55, HSP90, calcineurin, fitness cost, compensatory mutations, drug resistance evolution, petite mutants, mitochondrial respiration, Hsp90 inhibitors, calcineurin inhibitors, antifungal resistance
- MeSH terms
- Caspofungin, Antifungal Agents, Base Sequence, Female, Fungal Proteins, Glucosyltransferases, Humans, Microbial Sensitivity Tests, Middle Aged, Polymorphism, Genetic, Genome, Fungal, Sequence Analysis, DNA, HSP90 Heat-Shock Proteins, Evolution, Molecular, Calcineurin, Drug Resistance, Fungal, Candida glabrata, Echinocandins, Lipopeptides, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.